WallStSmart

AstraZeneca PLC (AZN)vsMonte Rosa Therapeutics Inc (GLUE)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 88608% more annual revenue ($62.38B vs $70.33M). AZN leads profitability with a 17.7% profit margin vs -186.2%. AZN earns a higher WallStSmart Score of 68/100 (B-).

AZN

Strong Buy

68

out of 100

Grade: B-

Growth: 6.7Profit: 8.5Value: 6.0Quality: 5.5
Piotroski: 6/9Altman Z: 1.48

GLUE

Hold

36

out of 100

Grade: F

Growth: 6.3Profit: 2.0Value: 5.0Quality: 7.5
Piotroski: 6/9Altman Z: 0.02
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AZNUndervalued (+11.8%)

Margin of Safety

+11.8%

Fair Value

$197.76

Current Price

$174.35

$23.41 discount

UndervaluedFair: $197.76Overvalued

Intrinsic value data unavailable for GLUE.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AZN5 strengths · Avg: 8.6/10
Market CapQuality
$293.73B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
21.3%9/10

Every $100 of equity generates 21 in profit

Operating MarginProfitability
29.6%8/10

Strong operational efficiency at 29.6%

EPS GrowthGrowth
23.5%8/10

Earnings expanding 23.5% YoY

Free Cash FlowQuality
$3.99B8/10

Generating 4.0B in free cash flow

GLUE3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
325.8%10/10

Revenue surging 325.8% year-over-year

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Price/BookValuation
2.4x8/10

Reasonable price relative to book value

Areas to Watch

AZN2 concerns · Avg: 3.0/10
P/E RatioValuation
26.8x4/10

Moderate valuation

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

GLUE4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$880.99M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-26.4%2/10

ROE of -26.4% — below average capital efficiency

Free Cash FlowQuality
$-42.54M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 29.6%. PEG of 1.35 suggests the stock is reasonably priced for its growth.

Bull Case : GLUE

The strongest argument for GLUE centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 325.8% demonstrates continued momentum.

Bear Case : AZN

The primary concerns for AZN are P/E Ratio, Altman Z-Score.

Bear Case : GLUE

The primary concerns for GLUE are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

AZN profiles as a mature stock while GLUE is a hypergrowth play — different risk/reward profiles.

GLUE carries more volatility with a beta of 1.38 — expect wider price swings.

GLUE is growing revenue faster at 325.8% — sustainability is the question.

AZN generates stronger free cash flow (4.0B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (68/100 vs 36/100), backed by strong 17.7% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Monte Rosa Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new precision small molecule drugs that employ the body's natural mechanisms to selectively break down therapeutically relevant proteins. The company is headquartered in Boston, Massachusetts.

Visit Website →

Want to dig deeper into these stocks?